Is 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating 4D Molecular Therapeutics, Inc. at current levels.
A $449M biotech with a once-every-three-years eye injection that could replace a $12B drug class, trading below cash equivalents.
Where FDMT is headed
Picture the wet AMD waiting room in 2028. Today it's a monthly conveyor belt of patients getting needles in their eyeballs to keep Eylea or Vabysmo working. The compliance drop-off after year one is brutal, roughly half of patients fall off the dosing schedule, and vision loss follows. 4D-150 is the bet that one intravitreal injection can produce anti-VEGF protein continuously inside the retina for two to three years. If the Phase 3 PRISM trial reads out cleanly in late 2027, FDMT goes from a clinical-stage curiosity to the company holding the only durable gene therapy answer to a market Regeneron and Roche currently split worth north of $12 billion annually.
Read the full Compass Direction on FDMT
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $9.23).
See the full FDMT analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating 4D Molecular Therapeutics, Inc. at current levels. A $449M biotech with a once-every-three-years eye injection that could replace a $12B drug class, trading below cash equivalents.
What is FDMT's Compass Score?
4D Molecular Therapeutics, Inc. scores 81/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for FDMT?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the FDMT page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.